Company Overview
OS Therapies Incorporated is a clinical stage biopharmaceutical entity dedicated to the identification, development, and commercialization of therapeutic treatments specifically for osteosarcoma and other solid tumors within the United States market. The company operates within the Healthcare sector and the Biotechnology industry, positioning it as a specialized player focused on advancing immunotherapies such as OST-HER2 for specific patient populations. With a current market capitalization of $49.65M, the company maintains a very small operational scale, employing only four individuals to drive its research and development initiatives. These valuation and revenue metrics indicate that OS Therapies is a micro-cap entity in the early stages of its commercialization journey, where the primary focus remains on pipeline progression rather than generating substantial annual revenue or operating profits.
Financial Health
The company's financial statements reveal a net income of $-20,256,220 over the trailing twelve months, while reported revenue and EBITDA figures are not available due to the company's current stage of development. The significant negative net income relative to the lack of reported revenue highlights a cost structure heavily weighted toward research, development, and operational overhead required to advance clinical candidates before commercial launch. Free cash flow stands at $-7,755,321, which indicates that the company is burning cash to fund its operations and pipeline activities, thereby limiting its current financial flexibility for external expansion or acquisitions. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are listed at 0.0%, reflecting the typical financial profile of pre-revenue biotechnology firms where costs are incurred prior to sales recognition. On the balance sheet, the company holds $1.88M in cash against a debt level that is not available for citation, resulting in a debt-to-equity ratio that is not available. The current ratio of 0.56 suggests that the company's current assets are insufficient to cover its current liabilities without additional financing or asset liquidation, indicating potential short-term liquidity constraints. Furthermore, the Return on Equity is -914.0% and the Return on Assets is -225.1%, metrics that reveal management is utilizing shareholder capital to fund high-risk development activities that have not yet resulted in profitable returns or positive asset utilization.
Valuation Assessment
Valuation multiples for OS Therapies include a Trailing P/E ratio that is not available and a Forward P/E of -4.24, the disparity between these metrics implying that the company has not yet achieved profitability and that earnings are currently negative rather than growing. The Price to Book ratio is 12.94, suggesting that the market values the company's equity at a significant premium compared to its book value, a common phenomenon in biotechnology where future pipeline potential is priced into current shares despite current losses. Alternative valuation metrics such as the Price to Sales ratio and EV/EBITDA of -2.51 are provided where data is available, indicating that traditional earnings-based valuation methods are not applicable due to the absence of profitable operations. The stock has traded between a 52-week high of $2.57 and a 52-week low of $1.12, placing the current share price in a range where it remains well below its recent peak, reflecting the high volatility typical of small-cap clinical stage companies. The Beta value is not available, preventing a direct assessment of the stock's volatility relative to the broader market, though the wide spread between the 52-week high and low suggests substantial price swings independent of general market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available, as the company has not yet generated sufficient revenue to calculate meaningful growth rates against prior periods. Consequently, there is no data to determine if earnings are growing faster or slower than revenue, as both growth metrics are absent from the financial records. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the firm reinvests all available earnings and cash reserves directly back into research, development, and the advancement of its clinical pipeline. The overall growth and income profile of OS Therapies is characterized by a complete absence of current income generation and traditional growth metrics, focusing entirely on the long-term potential of its osteosarcoma treatment pipeline rather than immediate financial returns.